Cash, cash equivalents, restricted cash, and short-term investments as of September 30, were $222.5 M compared to $280.7M as of December 31, 2021. Icosavax currently expects its cash balance to be sufficient to fund operations through at least 2024. "The past few months have marked a pivotal moment for Icosavax, as we advanced our vision of creating combination vaccine candidates targeting respiratory diseases for older adults. Specifically, we recently initiated a Phase 1 trial for IVX-A12, which is not only our first combination VLP vaccine candidate, but also the only bivalent vaccine candidate targeting RSV and hMPV to reach clinical development," said Adam Simpson, Chief Executive Officer of Icosavax. "As we continue to work to progress IVX-A12, we are excited by the multiple potential inflection points that are set up for next year. Notably, we anticipate the IVX-A12 Phase 1 topline interim data in mid-2023, as well as six- and twelve-month immunogenicity data from the Phase 1b extension of its RSV component IVX-121 by early- and mid-2023, respectively. In addition, during 2023 we expect to announce the selection of candidates for our COVID-19 and flu programs."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ICVX:
